• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Optical/Ophthalmic

IDE Group launches ophthalmic auto-injector

May 5, 2025 By Sean Whooley

IDE Group OKO auto-injector

IDE Group recently unveiled OKO, its new ophthalmic auto-injector for improving drug delivery precision and efficiency. The company says OKO addresses critical unmet needs in ophthalmology. It aims to improve precision, procedural efficiency and patient safety compared to existing adapted injection methods. Currently, intravitreal injections — essential injections for treating retinal diseases like wet age-related […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Optical/Ophthalmic Tagged With: IDE Group

SpyGlass Pharma shares positive data for drug-eluting intraocular lens

October 18, 2024 By Sean Whooley

SpyGlass Pharma Intraocular Lens IOL drug delivery platform

SpyGlass Pharma released 18-month follow-up data highlighting the potential of its intraocular lens (IOL)-based drug delivery platform. Data came from a first-in-human study of 23 patients with glaucoma or ocular hypertension. They received the IOL implant at the time of cataract surgery. The company reported a consistent sustained reduction of intraocular pressure (IOP) across all […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic Tagged With: SpyGlass Pharma

Clearside Biomedical’s drug-device combo study meets endpoints

October 9, 2024 By Sean Whooley

Clearside Biomedical Xipere SCS Microinjector

Clearside Biomedical (Nasdaq:CLSD) today announced that the ODYSSEY study of its drug-device combination achieved its primary and secondary outcomes. Alpharetta, Georgia-based Clearside develops the SCS Microinjector suprachoroidal injection device. It enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to […]

Filed Under: Clinical Trials, Drug-Device Combinations, Optical/Ophthalmic Tagged With: Clearside Biomedical

Eyenovia begins manufacturing next-gen drug delivery system

October 3, 2024 By Sean Whooley

Eyenovia microdose array print MAP ocular drug delivery device

Eyenovia (Nasdaq:EYEN) announced that it began manufacturing batches of its Mydcombi product for its next-generation delivery platform. Manufacturing registration batches of the FDA-approved Mydcombi mydriasis product marks a key step in the approval process for the company’s state-of-the-art Gen-2 Optejet dispensing platform, according to a news release. The company plans to have Mydcombi undergo 12-month […]

Filed Under: Business/Financial News, Drug-Device Combinations, Optical/Ophthalmic Tagged With: Eyenovia Inc.

Roche, Genentech to reintroduce drug-eluting eye implant in U.S. following 2022 recall

July 8, 2024 By Sean Whooley

Genentech Susvimo Implant Image 1 For Media

Roche subsidiary Genentech today reintroduced its Susvimo therapy for delivery via ocular implant in the U.S. following a recall. The FDA approved a post-approval supplement to Susvimo’s Biologics License Application (BLA). Approval reflects component-level updates made to the ocular implant and refill needle. Roche now plans to work to make Susvimo available in the U.S. […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance Tagged With: Genentech, Roche

Glaukos to exchange $230M in senior notes for common stock

June 14, 2024 By Sean Whooley

Glaukos logo

Glaukos (NYSE:GKOS) announced today that it entered into exchange agreements to repurchase approximately $230 million. The company entered into separate, privately negotiated exchange agreements with certain holders of 2.75% convertible senior notes due 2027. Pursuant to these agreements, the company agreed to repurchase $230 million of existing convertible notes for aggregate consideration of shares of […]

Filed Under: Business/Financial News, Funding Roundup, Implants, Optical/Ophthalmic Tagged With: Glaukos

Clearside Biomedical prices $15M offering

February 8, 2024 By Sean Whooley

Clearside Biomedical logo - updated

Clearside Biomedical (Nasdaq:CLSD) announced that it entered into a securities purchase agreement worth proceeds of approximately $15 million. The company agreed with institutional investors and an existing stockholder on the purchase and sale of 11.1 million shares of common stock and warrants. It set the offer price for one share of common stock and warrant […]

Filed Under: Business/Financial News, Drug-Device Combinations, Food & Drug Administration (FDA), Funding Roundup, Optical/Ophthalmic Tagged With: Clearside Biomedical

FDA approves Glaukos iDose TR glaucoma-treating drug delivery implant

December 14, 2023 By Sean Whooley

Glaukos iDose

Glaukos (NYSE:GKOS) announced today that the FDA approved a New Drug Application (NDA) for its iDose TR implant. The approval allows for one administration per eye of iDose TR (travoprost intracameral implant) 75 mcg. The indication for the prostaglandin analog covers the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic Tagged With: FDA, Glaukos

iStar Medical continues European MINIject rollout with first procedures in Ireland

October 31, 2023 By Sean Whooley

MINIject iSTAR

iStar Medical announced today that it expanded the commercial rollout of its MINIject device with the first implants in Ireland. MINIject, a minimally invasive glaucoma surgery (MIGS) device, treats open-angle glaucoma. Currently the only commercially available supraciliary MIGS implant, it has demonstrated meaningful and sustained performance, plus a favorable safety profile. The device combines the […]

Filed Under: Business/Financial News, Drug-Device Combinations, Implants, Optical/Ophthalmic Tagged With: iSTAR Medical

FDA issues warning about over-the-counter eye drops

October 30, 2023 By Sean Whooley

FDA-logo-new

The FDA issued a notice warning consumers about 26 over-the-counter eye drop products that could result in eye infections. In its notice, the FDA instructed consumers not to purchase and to immediately stop using these products. Using those eye drops could lead to the risk of infections that could result in partial vision loss or […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Optical/Ophthalmic, Recalls, Regulatory/Compliance Tagged With: Cardinal Health, CVS Health, FDA

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 31
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS